0001725160-24-000036.txt : 20240205 0001725160-24-000036.hdr.sgml : 20240205 20240205191623 ACCESSION NUMBER: 0001725160-24-000036 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240201 FILED AS OF DATE: 20240205 DATE AS OF CHANGE: 20240205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HAUSMAN DIANA CENTRAL INDEX KEY: 0001563992 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39263 FILM NUMBER: 24597549 MAIL ADDRESS: STREET 1: C/O ONCOTHYREON INC. STREET 2: 2601 FOURTH AVE, SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER NAME: FORMER CONFORMED NAME: HAUSMAN DIANE DATE OF NAME CHANGE: 20121207 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zentalis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001725160 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 823607803 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1359 BROADWAY, SUITE 801 CITY: NEW YORK STATE: NY ZIP: 10018 BUSINESS PHONE: (212) 433-3791 MAIL ADDRESS: STREET 1: 1359 BROADWAY, SUITE 801 CITY: NEW YORK STATE: NY ZIP: 10018 FORMER COMPANY: FORMER CONFORMED NAME: Zentalis Pharmaceuticals, LLC DATE OF NAME CHANGE: 20200107 FORMER COMPANY: FORMER CONFORMED NAME: Zeno Pharma, LLC DATE OF NAME CHANGE: 20171212 4 1 wk-form4_1707178572.xml FORM 4 X0508 4 2024-02-01 0 0001725160 Zentalis Pharmaceuticals, Inc. ZNTL 0001563992 HAUSMAN DIANA C/O ZENTALIS PHARMACEUTICALS, INC. 1359 BROADWAY, SUITE 801 NEW YORK NY 10018 0 1 0 0 Chief Medical Officer 0 Common Stock 2024-02-01 4 A 0 337500 0 A 377232 D Stock Option (Right to Buy) 11.69 2024-02-01 4 A 0 337500 0 A 2034-01-31 Common Stock 337500 337500 D Represents restricted stock units ("RSUs") granted to the Reporting Person in connection with Reporting Person's previously disclosed appointment as Chief Medical Officer, effective January 19, 2024. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in substantially equal annual installments over a four year period following the vesting commencement date of January 19, 2024, subject to the Reporting Person's continued service with the Issuer. The options were granted to the Reporting Person in connection with Reporting Person's previously disclosed appointment as Chief Medical Officer, effective January 19, 2024. The options will vest over four years in equal monthly installments from the vesting commencement date of January 19, 2024 until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. /s/ Andrea Paul, attorney-in-fact for Diana Hausman 2024-02-05